Company intelligence / Profile preview

Syqe Medical

Ownership: Private
Employees: ~116
Development stage: Commercial

Overview

Clinical trials demonstrate rapid pain reduction with minimal psychoactive effects; 92% of patients report improved quality of life; supported by real-world evidence and patient testimonials.

Therapeutic areas: Neurology
Modalities: DevicePlant-derived small molecule delivery system
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

SyqeAir Inhaler

Commercial

Indications: Chronic neuropathic pain, PTSD

Partnerships

Teva Pharmaceuticals (marketing/distribution)Ministry of Defense (Israel) (cooperation agreement)Meuhedet HMO (cooperation agreement)

Beyond the preview

Go deeper on Syqe Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syqe Medical.

Explore the full profile